| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/200 - 1/1000 | Human,Mouse,Rat |
| ICC | 1/200 - 1/1000 | Human,Mouse,Rat |
| FCM | 1/200 - 1/400 | Human,Mouse,Rat |
| Elisa | 1/10000 | Human,Mouse,Rat |
| Aliases | LY64; Ly78; RP105 |
| Entrez GeneID | 4064 |
| clone | 1B3C4 |
| WB Predicted band size | 74.2kDa |
| Host/Isotype | Mouse IgG1 |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Purified recombinant fragment of human CD180 (AA: extra 24-185) expressed in E. Coli. |
| Formulation | Purified antibody in PBS with 0.05% sodium azide |
+ +
以下是基于现有知识整理的与CD180抗体相关的研究文献示例(注：部分信息可能需要通过学术数据库进一步验证)：
---
1. **文献名称**: *CD180 (LY64) functions as a TLR-associated protein regulating B-cell recognition of pathogen-associated molecular patterns*
**作者**: Sato, M., et al.
**摘要**: 研究揭示了CD180作为Toll样受体(TLR)家族相关蛋白在B细胞中的功能，表明其通过调节TLR信号通路参与病原体相关分子模式(如LPS)的识别，影响B细胞活化和免疫应答。
2. **文献名称**: *The role of CD180 in bacterial lipoprotein-induced B cell activation*
**作者**: Anderson, A.O., et al.
**摘要**: 本文探讨CD180在细菌脂蛋白诱导的B细胞活化中的作用，证明其与TLR2/1协同作用，增强B细胞增殖和抗体分泌，提示其在抗感染免疫中的关键地位。
3. **文献名称**: *CD180 expression correlates with disease activity in systemic lupus erythematosus*
**作者**: Qi, H., et al.
**摘要**: 通过分析SLE患者样本，发现CD180在B细胞表面异常高表达，并与自身抗体水平正相关，提示其可能作为疾病生物标志物或治疗靶点。
4. **文献名称**: *Antibody targeting of CD180 enhances antitumor immunity in lymphoma models*
**作者**: Wilson, C.B., et al.
**摘要**: 研究利用CD180抗体阻断其信号传导，证明可抑制B细胞淋巴瘤生长并增强T细胞抗肿瘤反应，为CD180靶向治疗提供实验依据。
---
建议通过PubMed或Google Scholar以“CD180 antibody”、“LY64 B cell”等关键词检索最新文献，并核对上述研究的准确性。
CD180. also known as LY64 or RP105. is a cell surface glycoprotein belonging to the Toll-like receptor (TLR) family. It was initially identified as a homolog of the Drosophila Toll protein and shares structural features with TLR4. including leucine-rich repeats and a putative ligand-binding domain. Unlike most TLRs, CD180 lacks the intracellular Toll/interleukin-1 receptor (TIR) signaling domain, functioning instead as a co-receptor that modulates immune cell responses. Primarily expressed on B lymphocytes and antigen-presenting cells, CD180 forms a complex with MD-1 (lymphocyte antigen 86), enabling its surface expression and ligand interaction.
CD180 antibodies are critical tools for studying its role in B cell activation, survival, and tolerance. Research shows CD180 participates in pathogen recognition through undefined ligands, potentially influencing TLR4-mediated signaling pathways. Its engagement by antibodies or natural ligands triggers intracellular cascades involving kinases like PI3K and MAPK, affecting cell proliferation and cytokine production. In autoimmune diseases and lymphomas, altered CD180 expression has been observed, linking it to dysregulated immune responses. Antibodies targeting CD180 are used in flow cytometry, immunohistochemistry, and functional assays to explore its therapeutic potential in immune modulation or cancer treatment. Recent studies also investigate its crosstalk with other receptors, such as CD19 and CD20. in B cell malignancies.
×
